» Articles » PMID: 8696074

The Bioavailability of 26Al-labelled Aluminium Citrate and Aluminium Hydroxide in Volunteers

Overview
Journal Biometals
Specialty Biochemistry
Date 1996 Jul 1
PMID 8696074
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

A study was undertaken to determine the fraction of ingested aluminium taken up by two male volunteers, following their ingestion of either aluminium citrate or aluminium hydroxide. In addition, the effects of simultaneous citrate ingestion on the gastrointestinal absorption of aluminium from its hydroxide was studied. Volunteers received three oral doses of 26Al-labelled aluminium compound in water. The doses were administered directly into the stomach using a paediatric feeding tube. Blood samples were collected from the volunteers at 1, 4 and 24 h after administration, and their daily output of urine and faeces was collected for 6 days. These samples were analysed for their 26Al content using either coincidence gamma-counting or accelerator mass spectrometry. The uptake of aluminium was greatest following its administration in the citrate form and was least following intake as the aluminium hydroxide suspension. The co-administration of citrate, with the aluminium hydroxide suspension, was found to enhance the levels of 26Al uptake in both volunteers. Using a urinary excretion factor based on the results of previous studies, the fractional aluminium uptake from each of the species was calculated: aluminium citrate, 5.23 x 10(-3); aluminium hydroxide, 1.04 x 10(-4); aluminium hydroxide with citrate, 1.36 x 10(-3).

Citing Articles

Physiology-based toxicokinetic modelling of aluminium in rat and man.

Hethey C, Hartung N, Wangorsch G, Weisser K, Huisinga W Arch Toxicol. 2021; 95(9):2977-3000.

PMID: 34390355 PMC: 8380244. DOI: 10.1007/s00204-021-03107-y.


Aluminium toxicosis: a review of toxic actions and effects.

Igbokwe I, Igwenagu E, Igbokwe N Interdiscip Toxicol. 2020; 12(2):45-70.

PMID: 32206026 PMC: 7071840. DOI: 10.2478/intox-2019-0007.


Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Willhite C, Karyakina N, Yokel R, Yenugadhati N, Wisniewski T, Arnold I Crit Rev Toxicol. 2014; 44 Suppl 4:1-80.

PMID: 25233067 PMC: 4997813. DOI: 10.3109/10408444.2014.934439.


Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Damment S, Pennick M Clin Pharmacokinet. 2008; 47(9):553-63.

PMID: 18698878 DOI: 10.2165/00003088-200847090-00001.


Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Krewski D, Yokel R, Nieboer E, Borchelt D, Cohen J, Harry J J Toxicol Environ Health B Crit Rev. 2007; 10 Suppl 1:1-269.

PMID: 18085482 PMC: 2782734. DOI: 10.1080/10937400701597766.


References
1.
DOLL R . Review: Alzheimer's disease and environmental aluminium. Age Ageing. 1993; 22(2):138-53. DOI: 10.1093/ageing/22.2.138. View

2.
Partridge N, Regnier F, Reed W, White J, Hem S . Contribution of soluble aluminium species to absorption of aluminium from the rat gut in situ. Clin Sci (Lond). 1992; 83(4):425-30. DOI: 10.1042/cs0830425. View

3.
Priest N . The bioavailability and metabolism of aluminium compounds in man. Proc Nutr Soc. 1993; 52(1):231-40. DOI: 10.1079/pns19930055. View

4.
Talbot R, Newton D, Priest N, Austin J, Day J . Inter-subject variability in the metabolism of aluminium following intravenous injection as citrate. Hum Exp Toxicol. 1995; 14(7):595-9. DOI: 10.1177/096032719501400707. View

5.
Greger J, Baier M . Excretion and retention of low or moderate levels of aluminium by human subjects. Food Chem Toxicol. 1983; 21(4):473-7. DOI: 10.1016/0278-6915(83)90105-9. View